ScholarLens Back to search
2010•Zhongguo yiyuan ganranxue zazhiRequires access

Cefoperazone/sulbactam for ventilator-associated pneumonia.

Yang RuoSong, Zhu Ping-guang, Lei Chen, Wang BiJiong, Zaichun Deng

Open publisher page 0 citations

Abstract

OBJECTIVE To evaluate the clinical efficacy of cefperazone/sulbactam for ventilator-associated pneumonia(VAP). METHODS Totally 136 cases of VAP patients were randomized into cefoperazone/sulbactam group and ceftazidime group, and sputum culture was underwent for each case before and after treatment. RESULTS The total efficacy rates and bacterial eradication rates in cefoperazone/sulbactam group and ceftazidime group were 91.18% and 94.44% and 70.59% and 74.29%, respectively, and the differences between the two groups were statistically significant. CONCLUSIONS It suggests that cefoperazone/sulbactam is a more effective drug for VAP.

About this research paper

What this paper is about

OBJECTIVE To evaluate the clinical efficacy of cefperazone/sulbactam for ventilator-associated pneumonia(VAP). METHODS Totally 136 cases of VAP patients were randomized into cefoperazone/sulbactam group and ceftazidime group, and sputum culture was underwent for each case before and after treatment. RESULTS The total efficacy rates and bacterial eradication rates in cefoperazone/sulbactam group and ceftazidime group were 91.18% and 94.44% and 70.59% and 74.29%, respectively, and the differences between the two groups were statistically significant. CONCLUSIONS It suggests that cefoperazone/sulbactam is a more effective drug for VAP.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE To evaluate the clinical efficacy of cefperazone/sulbactam for ventilator-associated pneumonia(VAP). METHODS Totally 136 cases of VAP patients were randomized into cefoperazone/sulbactam group and ceftazidime group, and sputum culture was underwent for each case before and after treatment. RESULTS The total efficacy rates and bacterial eradication rates in cefoperazone/sulbactam group and ceftazidime group were 91.18% and 94.44% and 70.59% and 74.29%, respectively, and the differences between the two groups were statistically significant. CONCLUSIONS It suggests that cefoperazone/sulbactam is a more effective drug for VAP.

Key concepts: Cefoperazone, Sulbactam, Ceftazidime, Medicine, Ventilator-associated pneumonia, Sputum, Pneumonia, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Cefoperazone/sulbactam for ventilator-associated pneumonia. — Research Paper | ScholarLens